Hepion Pharmaceuticals, Inc. (HEPA) |
|
0.3998 -0 (-0.05%)
|
11-25 12:59 |
|
Open: |
0.3899 |
Pre. Close: |
0.4 |
|
High:
|
0.41 |
Low:
|
0.3872 |
|
Volume:
|
115,096 |
Market Cap:
|
30(M) |
|
|
|
Technical analysis |
as of: 2022-11-25 1:57:38 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 0.61 One year: 0.73 |
| Support: |
Support1: 0.36 Support2: 0.3 |
| Resistance: |
Resistance1: 0.52 Resistance2: 0.62 |
| Pivot: |
0.42  |
| Moving Average: |
MA(5): 0.42 MA(20): 0.46
MA(100): 0.55 MA(250): 0.81 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 13.8 %D(3): 20.2 |
| RSI: |
RSI(14): 40.8 |
| 52-week: |
High: 1.38 Low: 0.36 |
| Average Vol(K): |
3-Month: 181 (K) 10-Days: 279 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ HEPA ] has closed above bottom band by 33.2%. Bollinger Bands are 0.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.41 - 0.41 |
0.41 - 0.42 |
|
Low:
|
0.38 - 0.38 |
0.38 - 0.39 |
|
Close:
|
0.4 - 0.4 |
0.4 - 0.4 |
|
Company Description |
|
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey. |
Headline News |
Sat, 26 Nov 2022
Review: Toshiba CAF-Z85US(W) Smart Air Purifier For Large Rooms - Forbes
Fri, 25 Nov 2022
Coway’s Airmega AP-1512HH True HEPA Air Purifier falls to new 2022 low of $133, more - 9to5Toys
Fri, 25 Nov 2022
HEPA-filter Vacuums Are Up to 50% Off this Cyber Monday—Including Dyson - Health.com
Wed, 23 Nov 2022
National Advertising Division Finds Certain HEPA Claims for Shark Air Purifiers Supported; SharkNinja Appeals Recommendation to Modify or Discontinue Others - Lexology
Tue, 22 Nov 2022
Is Hepion Pharmaceuticals Inc (HEPA) Stock a Smart Investment Tuesday? - InvestorsObserver
Mon, 21 Nov 2022
The 7 Best Air Purifiers For Mold, Mildew & Musty Smells | mindbodygreen - mindbodygreen
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
76 (M) |
| Shares Float |
76 (M) |
|
% Held by Insiders
|
0.1 (%) |
|
% Held by Institutions
|
9.3 (%) |
|
Shares Short
|
581 (K) |
|
Shares Short P.Month
|
691 (K) |
Stock Financials |
|
EPS
|
-0.44 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.75 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-30.9 |
|
Return on Equity (ttm)
|
-55.8 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.59 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-38 (M) |
|
Levered Free Cash Flow
|
-26 (M) |
Stock Valuations |
|
PE Ratio
|
-0.91 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.53 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.82 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2019-06-02 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
